Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 8, 1999, Pages 1899-1904

  Ungvari, Zoltan ^b   Pacher, Pal ^b   Rischák, Katalin ^b   Szollár, Lajos ^b   Koller, Akos ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

Acetylcholine; Histamine; Homocysteinemia; Microcirculation; Nitri c oxide; Norepinephrine

Indexed keywords

ACETYLCHOLINE; CATALASE; HISTAMINE; METHIONINE; N(G) NITROARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; NORADRENALIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; GRACILIS MUSCLE; HYPERHOMOCYSTEINEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

EID: 0032787873     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.8.1899     Document Type: Article

References (40)

1. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Serlon G, Upson B. Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation. 1989;79: 1180-1188.
2. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989;114:473-501.
3. Clarke R, Daly L, Robinson K, Naughten E, Cahalene S, Fowler B, Graham. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;313:709-715.
4. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
5. McCully KS. Vascular pathophysiology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol. 1969;56: 111-128.
6. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med. 1995;332:328-329.
7. Verhoef P, Kok FJ, Kruyssen DACM, Schouten EG, Witteman JCM, Grobbee DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins, of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:989-995.
8. Hladovec J. Methionine, pyridoxine and endothelial lesion in rats. Blood Vessels. 1980;17:104-109.
9. Matthias D, Becker CH, Riezler R. Kindling PH. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis. 1996;122:201-216.
10. Harker LA, Ross R, Slichter S, Scott RC. Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731-741.
11. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75:895-901.
12. van den Berg M, Boers GHJ, Franken DG, Blom HJ, van Kamp GJ, Jakobs C, Rauwerda JA, Kluft C, Stehouwert CDA. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995;25:176-181.
13. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not their heterozygous parents. J Am Coll Cardiol. 1993;22:854-858.
14. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997;95:1119-1121.
15. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Farad FM, Malinow RM, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996;98:24-29.
16. Lentz SR. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol. 1997;17:2930-2934.
17. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res. 1980;18:113-121.
18. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-denved tissue factor activity in rats. FASEB J. 1997;11:1157-1168.
19. Durand P, Fortin LJ, Lussier-Cacan S, Davignon J, Blache D. Hyperhomocysteinemia induced by folic acid deficiency and methionine load: applications of a modified HPLC method. Clin Chim Acta. 1996;252: 83-93.
20. Koller A, Sun D, Messina EJ, Kaley G. L-Arginine analogues blunt prostaglandin-related dilation of arterioles. Am J Physiol. 1993;26: H1194-H1199.
21. Champion HC, Kadowitz PJ. NO release and the opening of K+ATP channels mediate vasodilator responses to histamine in the cat. Am J Physiol. 1997;273:H928-H937.
22. Ulbink JB, Vermak WJH, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in humans serum. J Chromatogr B Biomed Appl. 1991;565:441-446.
23. Sun D, Kaley G, Koller A. Characteristics and origin of myogenic response in isolated gracilis muscle arterioles. Am J Physiol. 1994;266: H1177-H1183.
24. Huang A, Sun D, Kaley G, Koller A. Superoxide released to high intraluminal pressure reduces nitric oxide-mediated shear stress- and agonist-induced dilations. Circ Res. 1998;83:960-965.
25. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factor for coronary artery disease. Circulation. 1995;92: 2855-2830.
26. Smolin LA, Crenshaw TD, Kurtycz D, Benevenga NJ. Homocyst(e)ine accumulation in pigs fed diets deficient in vitamin B6: relationship to atherosclerosis. J Nutr. 1983;113:2122-2133.
27. Lin J, Kang S, Zhou J, Wong PWK. Homocysteinemia in rats induced by folic acid deficiency. Life Sci. 1988;44:319-325.
28. Surtess R, Leonard J, Austin S. Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet. 1991;338:1550-1554.
29. Egashira K, Inou T, Irooka T, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 1993;91:29-37.
30. Kuo L, Davis MJ, Cannon MS, Chilian WM. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation: restoration of endothelium-dependent responses by L-arginine. Circ Res. 1992;70:465-476.
31. Kaley G, Koller A, Rodenburg JM, Messina EJ, Wolin MS. Regulation of arteriolar tone and responses via L-arginine pathway in skeletal muscle. Am J Physiol. 1992;262:H987-H992.
32. Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation. 1990;81:1586-1593.
33. Frauscher G, Karnaukhova E, Muehl, Hoeger H, Lubec B. Oral administration of homocysteine leads to increased plasma triglycerides and homocysteic acid: Additional mechanisms in homocysteine induced endothelial damage? Life Sci. 1995;57:813-817.
34. Koller A, Huang A. Impaired nitric oxide-mediated now-induced dilation in arterioles of spontaneously hypertensive rats. Circ Res. 1994;74: 416-421.
35. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308-318.
36. Loscalzo J. The oxidative stress of hyperhomocyst(e)inemia. J Clin Invest. 1996;98:5-7.
37. Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis. 1996;122: 163-172.
38. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77:1370-1376.
39. Upchurch GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272: 17012-17017.
40. Hempel LS. Homocysteine decreases endothelial cell glutathione, increasing the sensitivity to oxidants. Circ. 1998;98(suppl):I-386. Abstract.